To evaluate the effects of canagliflozin on plasma volume , urinary glucose excretion ( UGE ) , fasting plasma glucose ( FPG ) , glycated haemoglobin ( HbA@c ) and additional measures of fluid/electrolyte balance in patients with type @ diabetes on background therapy with metformin and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers .